Ruhinder Singh
Austin, TXNPI 1710646013
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 499 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,138 and has fallen 62.5% since, to $1,177 in 2025.
Across 499 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- AbbVie$868
- Corium, LLC$634
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$614
- Axsome Therapeutics, Inc.$573
- plus $4K from 21 others
What the payments were for
- Food & beverage$9,211100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 66 | $1,275 |
| Alkermes, Inc. | 68 | $1,004 |
| AbbVie | 36 | $868 |
| Corium, LLC | 29 | $634 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $614 |
| Axsome Therapeutics, Inc. | 27 | $573 |
| Lundbeck LLC | 22 | $459 |
| Supernus Pharmaceuticals, Inc. | 40 | $447 |
| Teva Pharmaceuticals USA, Inc. | 21 | $419 |
| Neurocrine Biosciences, Inc. | 12 | $372 |
| Tris Pharma Inc | 21 | $364 |
| Johnson & Johnson | 14 | $357 |
| Idorsia Pharmaceuticals US Inc | 23 | $346 |
| Neos Therapeutics, LP | 21 | $305 |
| Ironshore Pharmaceuticals Inc. | 18 | $283 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $234 |
| Bausch Health US, LLC | 11 | $220 |
| Noven Therapeutics, LLC | 7 | $156 |
| Merck | 4 | $49 |
| Arbor Pharmaceuticals, Inc. | 3 | $45 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Vertical Pharmaceuticals, LLC | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| OWP Pharmaceuticals, Inc. | 2 | $26 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Avion Pharmaceuticals | 1 | $20 |
| Biogen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 11 | $128 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.